In this "Test in Focus" episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., discusses Mayo Clinic Laboratories’ new hereditary oncology test offerings, which use next-generation sequencing to detect germline alterations associated with increased risk for various cancers. Our comprehensive panels, disease-specific panels, and single gene assays leverage the clinical expertise of Mayo Clinic physicians, enabling individualized insights on a patient’s risk of developing secondary cancers or a hereditary cancer syndrome.

“We know inherited genetic alterations contribute to about 10% to 20% of cancers overall,” Dr. Shen says. “However, more studies are showing that universal genetic testing actually detects more patients with hereditary cancer syndromes than a guideline-based approach.”

Test results can indicate the likelihood of a clinical diagnosis of a hereditary cancer syndrome, advance understanding of a patient’s risk of developing additional cancers, assist in management and treatment decisions, and rule out hereditary causes, Dr. Shen says. The biggest benefit of using Mayo Clinic testing, however, is access to expert-backed testing across the oncological spectrum.

“Cancers can result from both somatic and germline mutations,” Dr. Shen says. “This series of new genetic panels completes our comprehensive cancer testing menu and allows us to offer a one-stop shop genetic service to physicians and cancer patients.”

Listen to learn more.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

XCP  | Hereditary Expanded Panel

COMCP  | Hereditary Common Cancer Panel

The latest from Test in Focus

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less